WEST LAFAYETTE, Ind., Feb. 27, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that data from ongoing phase 1 trials of Endocyte’s SMDCs EC1456 and EC1169 will be presented at the 13th International Congress on Targeted Anticancer Therapies being held March 2 - 4, 2015, in Paris, France.
The poster presentations show the current status of the Phase 1 dose-escalation studies of Endocyte’s wholly-owned folate receptor (FR)-targeting folate-tubulysin conjugate, EC1456, and prostate specific membrane (PSMA)-targeting tubulysin conjugate, EC1169. The EC1456 poster was selected as one of the “TAT 2015 Best Poster Awards” and was selected for oral presentation.
The presentation materials will be available on Endocyte’s website following presentation at the conference.
Presentations are as follows:
| Oral Presentation: | A Phase 1 Study of 2 Different Schedules of the Folic Acid-Tubulysin Small-Molecule Drug Conjugate EC1456 in Patients with Advanced Solid Tumors |
| When: | Wednesday, March 4, 12:40 p.m. – 1:00 p.m. CET |
| Session Title: | Poster Awarding Ceremony |
| Abstract #: | P1.08 |
| Title: | A Phase 1 Study of 2 Different Schedules of the Folic Acid-Tubulysin Small-Molecule Drug Conjugate EC1456 in Patients with Advanced Solid Tumors |
| When: | Monday, March 2, 6 p.m. – 7:30 p.m. CET |
| Session Title: | Poster Session 1: Clinical Studies |
| Abstract #: | P1.05 |
| Title: | A Phase 1 Study of 2 Different Schedules of the PSMA-Tubulysin Small-Molecule Drug Conjugate EC1169 in Patients with Recurrent Metastatic Castration-Resistant Prostate Cancer (MCRPC) |
| When: | Monday, March 2, 6 p.m. – 7:30 p.m. CET |
| Session Title: | Poster Session 1: Clinical Studies |
About EC1456
EC1456 is an investigational proprietary, injectable, SMDC consisting of folate (vitamin B9) linked to a potent cytotoxic agent, tubulysin B hydrazide (TubBH). EC1456 is wholly owned by Endocyte. TubBH is a member of the tubulysin class of anti-neoplastic agents that inhibit the polymerization of tubulin into microtubules, a critical component during cell division. The targeting ligand folate, essential for cell division, has been investigated with vintafolide. EC1456 is currently being evaluated in a Phase 1 study in patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT01999738).
About EC1169
EC1169 is an investigational proprietary, injectable, SMDC consisting of a PSMA targeting ligand (DUPA analog) linked to a potent cytotoxic agent, tubulysin B hydrazide (TubBH). EC1169 is wholly owned by Endocyte. TubBH is a member of the tubulysin class of anti-neoplastic agents that inhibit the polymerization of tubulin into microtubules, a critical component during cell division. EC1169 is currently being evaluated in a Phase 1 study in patients with recurrent metastatic, castration-resistant prostate cancer (MCRPC) (ClinicalTrials.gov Identifier: NCT02202447).
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company’s SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly potent drugs into these cells. The companion imaging agents are designed to identify patients whose disease expresses the molecular target of the therapy and who therefore may be more likely to benefit from treatment. For more information, visit http://www.endocyte.com.
Endocyte Forward-Looking Statement
Certain of the statements made in this press release are forward-looking. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks that the company may experience delays in the completion of its clinical trials (whether caused by competition, adverse events, patient enrollment rates, unavailability of clinical trial materials, regulatory issues or other factors); risks that data from its clinical trials may not be indicative of subsequent clinical trial results; risks related to the safety and efficacy of the company’s product candidates, the goals of its development activities, estimates of the potential markets for its product candidates, estimates of the capacity of manufacturing and other facilities required to support its product candidates, projected cash needs, and expected financial results. More information about the risks and uncertainties faced by Endocyte, Inc. is contained in the company’s periodic reports filed with the Securities and Exchange Commission. Endocyte, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Stephanie Ascher, Stern Investor Relations, Inc. (212) 362-1200, stephanie@sternir.com
Help employers find you! Check out all the jobs and post your resume.
